Loading...
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
Background Blinatumomab is a BiTE(®) immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). AIMS: To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in...
Na minha lista:
| Udgivet i: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8026950/ https://ncbi.nlm.nih.gov/pubmed/33734596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3731 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|